Nofoxil Tenofovir Disoproxil Fumarate Tablet 300mg for Anti HIV

Model NO.: DAWATDF0001 Usage Mode: For oral administration State: Solid Type: Biological Products Name: Tenofovir Disoproxil Fumarate Tablet OEM: Acceptable Sample: Free Supply Transport Package: 30tablets/Bottle Origin: China Application: Internal Medicine Suitable for: Elderly, Children, Adult Shape: Tablet Pharmaceutical Technology: Chemical Synthesis Administration Route: Oral Certification: GMP Trademark: Nofoxil Specification: 300mg HS Code: 3002903090 Nofoxil Tenofovir Disoproxil Fumarate Tablet 300mg for Anti HIV
 

Specification	300mg
Package	30tablets/bottle

Tenofovir disoproxil is an antiretroviral medication used to prevent and treat HIV/AIDS and to treat chronic hepatitis B. The active substance is tenofovir, while tenofovir disoproxil is a prodrug that is used because of its better absorption in the gut.

Medical uses
Tenofovir disoproxil fumarate (tenofovir DF) is a bioavailable prodrug of tenofovir, a potent nucleotide analogue reverse-transcriptase inhibitor with activity against human immunodeficiency virus (HIV) and hepatitis B virus. It is administered as a single 300-mg tablet once daily. It was approved for the treatment of HIV infection on the basis of data from clinical trials demonstrating activity in treatment-experienced patients, and it was subsequently shown to be effective when used as a component of initial therapy. Tenofovir DF is active against some nucleoside-resistant strains of HIV. However, cross-resistance is associated with multiple thymidine analogue mutations that include 41L or 210W. The signature mutation is the K65R mutation, which causes variable loss in susceptibility to tenofovir DF, . Tenofovir DF has been well tolerated in clinical trials with durations of follow-up up to 96 weeks. It is associated with more-favorable lipid profiles than and has not been associated with the mitochondrial toxicity attributed to other nucleoside analogues.

Tenofovir disoproxil fumarate (tenofovir DF) is an orally bioavailable prodrug of tenofovir. It is the first nucleotide analogue reverse-transcriptase inhibitor (NtRTI) to have been approved by the US Food and Drug Administration (FDA) for the treatment of HIV infection. Since its approval in October 2001, this analogue of adenine 5′ monophosphate has quickly become a widely used component of antiretroviral regimens for both treatment-naive and -experienced patients on the basis of its efficacy and tolerability in several clinical trials.

Contact us if you need more details on Tenofovir. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Tenofovir、Tenofovir. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Anti-Hiv Drug